Teclozan is a synthetic antimicrobial agent that was first synthesized in the 1960s. It is a benzimidazole derivative with a broad spectrum of activity against various parasites, including cestodes, trematodes, and protozoa. Teclozan's mode of action involves interfering with the parasite's energy production by inhibiting the enzyme fumarate reductase. It has been investigated as a potential treatment for various parasitic infections, including schistosomiasis, fascioliasis, and giardiasis. Teclozan has demonstrated promising results in preclinical studies, but it has not yet been widely used clinically due to potential side effects, such as gastrointestinal disturbances and liver toxicity. Further research is ongoing to understand its efficacy and safety profile better. Teclozan's importance lies in its potential as a novel therapeutic agent for parasitic infections, particularly in regions where these diseases are prevalent. Studies on teclozan aim to optimize its therapeutic index and explore its use in combination with other drugs to enhance its effectiveness. Its unique mechanism of action and broad spectrum of activity make it a promising candidate for further investigation.'
teclozan: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 21723 |
| CHEMBL ID | 1788387 |
| CHEBI ID | 135803 |
| SCHEMBL ID | 635666 |
| MeSH ID | M0069113 |
| Synonym |
|---|
| teclozanum [inn-latin] |
| teclosine |
| brn 2825422 |
| n,n'-(1,4-phenylenebis(methylene))bis(2,2-dichloro-n-(2-ethoxyethyl)acetamide) |
| teclosan |
| nsc 107433 |
| teclozine |
| acetamide, n,n'-(1,4-phenylenebis(methylene))bis(2,2-dichloro-n-(2-ethoxyethyl)- |
| teclozan [usan:inn] |
| win am 13146 |
| n,n'-bis(dichloroacetyl)-n,n'-bis(2-ethoxyethyl)-1,4-xylylenediamine |
| acetamide, n,n'-(p-phenylenedimethylene)bis(2,2-dichloro-n-(2-ethoxyethyl)- |
| einecs 226-934-0 |
| n,n'-(p-phenylenedimethylene)bis(2,2-dichloro-n-(2-ethoxyethyl)acetamide) |
| 2,2-dichloro-n-(4-(((dichloroacetyl)(2-ethoxyethyl)amino)methyl)benzyl)-n-(2-ethoxyethyl)acetamide |
| n,n'-(p-phenylenedimethylene)bis[2,2-dichloro-n-(2-ethoxyethyl)acetamide] |
| acetamide, n,n'-(p-phenylenedimethylene)bis[2,2-dichloro-n-(2-ethoxyethyl)- |
| acetamide, n,n'-[1,4-phenylenebis(methylene)]bis[2,2-dichloro-n-(2-ethoxyethyl)- |
| 2,2-dichloro-n-[[4-[[(2,2-dichloroacetyl)-(2-ethoxyethyl)amino]methyl]phenyl]methyl]-n-(2-ethoxyethyl)acetamide |
| falmonox (tn) |
| teclozan (usan/inn) |
| D06051 |
| win 13,146 |
| n,2-dichloro-n-(2-ethoxyethyl)acetamide] |
| nsc-107433 |
| falmonox |
| acetamide,n'-(p-phenylenedimethylene)bis[2,2-dichloro-n-(2-ethoxyethyl)- |
| teclozan |
| nsc107433 |
| acetamide,n'-[1,4-phenylenebis(methylene)]bis[2,2-dichloro-n-(2-ethoxyethyl)- |
| win 13146 |
| n,n'-(p-xylylene)bis(n-ethoxyethyldichloroacetamide) |
| 5560-78-1 |
| CHEBI:135803 |
| k9rif0coub , |
| unii-k9rif0coub |
| teclozanum |
| win-13146 |
| CHEMBL1788387 |
| SCHEMBL635666 |
| teclozan [who-dd] |
| teclozan [inn] |
| teclozan [mart.] |
| teclozan [usan] |
| teclozan [mi] |
| DTXSID00204147 |
| DB13205 |
| Q7692717 |
| nsc 107433; teclosan; teclosine;nsc 107433; teclosan; teclosine |
| MS-29325 |
| EX-A5699 |
| CS-0015876 |
| HY-19594 |
| win-am 13146 |
| Class | Description |
|---|---|
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (44.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||